Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity

Abstract:
A needle-free vaccine platform that elicits a robust immune response against a wide array of viruses and bacteria has been awarded a U.S. patent. The University of Michigan holds the patent and NanoBio Corporation, a spin-off from the university, licenses the patent and its associated technology.

New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity

ANN ARBOR, MI | Posted on January 30th, 2008

The intranasal vaccines, produced using NanoBio's nanoemulsion technology, have elicited a dramatic immune response in animals vaccinated against influenza, anthrax, hepatitis B and other diseases. In some cases, the immune response is exponentially higher than what is required to provide adequate protection against infection. Such dramatic levels of immunity would confer significantly higher levels of protection to the vaccinated population at large compared with current injectable vaccines.

Because the vaccines trigger such robust immunity, scientists anticipate they will be able to reduce vaccine antigen quantities to a fraction of what current vaccines require, while still mounting an overwhelming immune response.

This "antigen-sparing" capability would enable scientists to rapidly produce large quantities of vaccines using miniscule amounts of antigen, a critical factor when faced with a disease pandemic or biological warfare.

"We have shown that when we mix our nanoemulsion with whole virus or a recombinant protein antigen and apply it to the naso-pharynx, the resulting vaccine elicits strong mucosal and systemic immunity," said James R. Baker Jr., M.D., founder and Chairman of NanoBio Corporation. "The nanoemulsion serves as an adjuvant to boost immune response against a specific antigen."

NanoBio is in various stages of testing its extensive pipeline of mucosal vaccines for influenza, bird flu, hepatitis B, HIV, RSV, small pox, anthrax and other viral and bacterial infections. Final results from the influenza vaccine study in ferrets are expected this quarter, and human tests with the influenza and hepatitis B vaccines are being planned.

The newly awarded patent covers the methods and compositions of formulating nanoemulsion vaccines, a unique coupling of oil, water, and antimicrobial surfactant together with antigens from specific pathogens.

Studies in animals demonstrate these vaccines easily penetrate the mucous membrane, where dendritic cells rapidly engulf the antigen and present it to the immune system. This rapid awakening of the immune system via the intranasal route negates the need for inflammatory stimulants used in traditional vaccines, which can cause pain and swelling at the site of vaccination, said Dr. Baker.

"We present antigen in an optimal location where it can most directly access the immune system," added Baker. "As a result, there is no need to prime the immune system with immunostimulants in order to provoke its recognition of the antigens."

Moreover, the vaccine requires no harsh chemicals to attenuate the whole virus and render it harmless, because the nanoemulsion itself kills the antigen. Advantages of the nanoemulsion vaccines include:

-- nasal delivery, the entry point of most respiratory infections -- development of rapid mucosal immunity followed by systemic immunity -- antigen-sparing capability -- thermally stable, requires no refrigeration -- needle-free, easy to administer

The development of the nanoemulsion platform began in 1998 and is supported, in part, by a $6.3 million grant from the Bill and Melinda Gates Foundation to the Michigan Nanotechnology Institute for Medicine and Biological Sciences, which is led by Dr. Baker. The new patent for nanoemulsion vaccines (#7,314,624 B2) is licensed to NanoBio Corporation on an exclusive, worldwide basis. With this new patent, NanoBio now holds five U.S. patents and has filed numerous additional applications in various jurisdictions.

####

About NanoBio Corporation
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

For more information, please click here

Contacts:
NanoBio® Corporation

Address:2311 Green Road, Suite A
Ann Arbor, Michigan 48105
Telephone:734.302.4000

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Springer and Tsinghua University Press present the second Nano Research Award: Paul Alivisatos of the University of California Berkeley receives the honor for outstanding contributions in nanoscience July 30th, 2015

European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015

Take a trip through the brain July 30th, 2015

This could replace your silicon computer chips: A new semiconductor material made from black phosphorus may be a candidate to replace silicon in future tech July 30th, 2015

Nanomedicine

European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015

Take a trip through the brain July 30th, 2015

Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015

Newly-Developed Polymers Control Size of Nanoparticles during Production Process July 30th, 2015

Announcements

Take a trip through the brain July 30th, 2015

This could replace your silicon computer chips: A new semiconductor material made from black phosphorus may be a candidate to replace silicon in future tech July 30th, 2015

Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015

Controlling Dynamic Behavior of Carbon Nanosheets in Structures Made Possible July 30th, 2015

Patents/IP/Tech Transfer/Licensing

Quantum networks: Back and forth are not equal distances! July 28th, 2015

Reshaping the solar spectrum to turn light to electricity: UC Riverside researchers find a way to use the infrared region of the sun's spectrum to make solar cells more efficient July 27th, 2015

Smarter window materials can control light and energy July 22nd, 2015

Magnetic nanoparticles could be key to effective immunotherapy: New method moves promising strategy closer to clinical use July 15th, 2015

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Springer and Tsinghua University Press present the second Nano Research Award: Paul Alivisatos of the University of California Berkeley receives the honor for outstanding contributions in nanoscience July 30th, 2015

European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015

Publication on Atomic Force Microscopy based nanoscale IR Spectroscopy (AFM-IR) persists as a 2015 top downloaded paper July 29th, 2015

UT Dallas nanotechnology research leads to super-elastic conducting fibers July 24th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project